Rituximab monotherapy for patients with recurrent primary CNS lymphoma. - Wikidata - awgldk - TriplyDB

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

http://www.wikidata.org/entity/Q34686155

about

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma It is time to include patients with brain tumors in phase I trials in oncology Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.Progress in central nervous system lymphomas.High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lympho Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience Complications of immunosuppressive/immunomodulatory therapy in neurological diseases.New approaches in primary central nervous system lymphoma.How I treat CNS lymphomas.Recent advances in treatment of primary central nervous system lymphoma.Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma.Methotrexate re-challenge for recurrent primary central nervous system lymphoma A 60-year-old Indian male with altered sensorium and extensive lymphoma of the scalp Pathogenesis and management of primary CNS lymphoma.Management of elderly patients with primary central nervous system lymphoma.Diagnosis and treatment of primary CNS lymphoma.Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.Recurrent or refractory primary central nervous lymphoma: therapeutic considerations.Present and future treatment options for primary CNS lymphoma.Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma The Challenge of Primary Central Nervous System Lymphoma.Diagnosis and Management of Leukemic and Lymphomatous Meningitis.Primary central nervous system lymphoma: essential points in diagnosis and management.Lymphomatoid granulomatosis of the brain: A case report.Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.Central nervous system lymphoma presenting as trigeminal neuralgia: A diagnostic challenge.Reply to M.C. Chamberlain.B Cell Therapy for Multiple Sclerosis: Entering an Era.Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

P2860

Q26748601-29073F73-C71B-4D4A-9924-7D83DB789C8B Q27013785-68420F66-9A0C-47B6-B16B-7FDE1F71BB96 Q30359570-4BBEE934-2772-4898-881F-91A36665C59C Q30457046-ECEBB853-3ACF-4735-BBF3-BC871BB40853 Q30859319-BC415C96-3D44-4864-96E8-63ADC9A27DD2 Q33824350-9AC50828-2F52-4517-A6F2-7C36F9AAF10A Q33934406-CD3D5450-16CC-48E4-A887-3B4F8415AA24 Q33981252-D253ED46-D26C-4588-BB7D-34032B274508 Q34640550-66278E65-0C1B-4FD2-9DCE-96C40457584F Q34943963-07B589F2-5594-4190-B974-611CFDE751E3 Q35802782-438ADDB8-98B0-414B-B0E1-5244F19FE624 Q36584818-B93D03B5-BADC-4A35-839C-76B3E8E43C0C Q36712741-22FF4291-DEC5-4AC0-B04A-CC1838DF6A3A Q36825376-2F204B0F-7E64-4071-B9F4-41C23B984835 Q37013065-40664F7C-87DB-4BED-A589-1DDA62E2BF31 Q37088471-CB51EB9E-E11F-400B-8473-9EE8226C561A Q37215118-368988E2-96D4-4C4C-837E-2EDEFDF88019 Q37345440-EE5A9145-05A4-4FDB-B6B7-D7B41D21C629 Q37585056-94774192-2D06-42DD-9721-37D92B0A483B Q37600487-0AA3A525-AC20-4827-970C-59E58B7D7E71 Q37711536-01375CD1-50E6-48FD-AD6D-6B5072634BBE Q38010799-C8001C0B-8086-4521-AF53-AF882992DD11 Q38096927-D1DB0A04-6FCC-4369-A091-EF22A2C0C890 Q38106613-5CFFF16C-1C0E-4786-BA9F-7DF94AE5155F Q38119420-2117880D-AEC9-4CB5-9342-274FC424B29D Q38140000-B3935663-595E-44E5-B9E6-2251331FB4BF Q38587122-9CEDFADE-1DDB-4E3F-ABBF-743A26BD5D23 Q38779978-8F088F79-58A9-4C10-B6BC-53D847B9B99C Q39020652-A6638E26-117A-4944-9909-7E13F8888BC6 Q39126738-82C82205-42BF-451F-814B-7064A46378C1 Q39185721-285801E1-7748-49E8-96A9-943082A4AFA7 Q41108547-1AC1E1E0-1ED8-4D81-A05D-48667EF5C6FE Q41139081-E02F1B46-19E4-41FA-89AA-B393CA3B0467 Q41472355-E76B12E7-AFA9-4A42-917B-F780A8002619 Q42093585-8875C0B3-F3E7-4087-9085-C659FD39BDF4 Q42426074-2DCF0A64-AE4C-48B4-8344-2592D48B421D Q46583404-15345EB5-BAED-44EB-B9EC-BE809AB6813C Q47692369-FF1D2586-BACA-4F77-8EA2-A00A4977AEB0 Q47790904-FFC26757-A6D1-4393-B8A9-D5D4AEFA774A Q47813195-67131886-4EC7-4322-A244-A82E44B1198F

P2860

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

http://www.wikidata.org/entity/Q34686155

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@ast

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@en

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@nl

type

label

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@ast

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@en

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@nl

prefLabel

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@ast

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@en

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@nl

P1433

Q34686155-175ACF71-8558-4B5E-8917-A7EE36378A5F

P1476

Q34686155-66958693-C214-4956-A53E-0ED5357D64BF

P2093

Q34686155-4E92DCE7-AE0C-4D9A-8A09-7FC50931A8A5

Q34686155-5524459C-E861-46D4-AF87-35B978E37ADA

Q34686155-5A396CAD-0000-4CC8-B647-64CE9D489081

Q34686155-A81CE11A-F6B7-4068-AE5E-A6F21063A9B2

Q34686155-B40749B9-0F90-48CA-88B4-E4C25E3E35FB

Q34686155-D9685593-C650-49CC-B398-5E10CEFAFBF3

P2860

Q34686155-19767CB0-01F2-4246-9F94-5E2AE0BDF300

Q34686155-7CE68F4E-B387-4C89-85D7-4EEADC240D2C

Q34686155-8C867DF9-B544-49D2-9DEB-EBA8C4E208CE

Q34686155-EC245198-17A1-41D0-ABAC-66AE676996F6

Q34686155-FE8B5931-93D0-4FAB-9562-94C2DECAC5D6

P304

Q34686155-52015CDE-9157-470A-B9F7-40CD92FA2F02

P31

Q34686155-8187D95F-9C4F-45A9-89C1-0B731636F9B2

P356

Q34686155-965FD797-9686-4F4E-A468-9AD034EBC1C7

P407

Q34686155-0CA8D2C4-9AA7-4977-90AC-06460B75E698

P433

Q34686155-63896A9E-0DA6-43B4-912D-496E1431BEC2

P478

Q34686155-D5D3DC9E-A792-4B58-AA92-27303116E2A2

P577

Q34686155-73DC083E-EC59-4FDA-952B-8027E7974FA7

P698

Q34686155-6E41994C-C985-473E-B625-62A97B6F27F7

P921

Q34686155-59D6FBBC-3A39-4CF3-AF70-42FDEEB44702

P932

Q34686155-327B54F9-E1C9-4B91-A048-45B702C50CFB

P356

WNL.0B013E31820F2D94

P1433

P1476

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

@en

P2093

G J Lesser

http://www.w3.org/2001/XMLSchema#string

S A Grossman

http://www.w3.org/2001/XMLSchema#string

S Desideri

http://www.w3.org/2001/XMLSchema#string

T Mikkelsen

http://www.w3.org/2001/XMLSchema#string

T T Batchelor

http://www.w3.org/2001/XMLSchema#string

X Ye

http://www.w3.org/2001/XMLSchema#string

P2860

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.

First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.

Response criteria for phase II studies of supratentorial malignant glioma.

Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.

P304

929-930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E31820F2D94

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21383331

http://www.w3.org/2001/XMLSchema#string

P921

P932

3059144

http://www.w3.org/2001/XMLSchema#string